Product image of Hylvastam (Sodium Hydrogen Carbonate) supplied by GNH India

Hylvastam

Active Ingredient:
Sodium Hydrogen Carbonate
Origin:
EU

Hylvastam (Sodium Hydrogen Carbonate)

Sodium Hydrogen Carbonate, the active ingredient in Hylvastam, is an alkalinising agent presented as an intravenous solution for intravenous use. It is employed to correct acid‑base disturbances and to manage elevated serum potassium in clinical settings.

GNH India supplies Hylvastam as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres, oncology centres, pharmacies and clinics worldwide.

Manufacturer / TM Owner

Macure Pharma Aps

1
Pack/s
This product is added to your enquiry list

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

A minimum order value applies. Our team will confirm the exact amount or quantity after reviewing your requirements.

Indications & Clinical Uses

Hylvastam (sodium hydrogen carbonate) is used to address acid–base disorders and electrolyte imbalances.

  • Metabolic acidosis: restores normal blood pH by providing bicarbonate ions.
  • Hyperkalemia: promotes intracellular shift of potassium, helping lower serum potassium levels.
  • Drug overdose (e.g., tricyclic antidepressants): alkalinises urine to enhance drug elimination.
  • Cardiac arrest resuscitation: supports pH balance during advanced cardiac life support.

How It Works

  • Sodium hydrogen carbonate dissociates into sodium and bicarbonate ions after intravenous administration. The bicarbonate acts as a systemic buffer, combining with hydrogen ions to form carbonic acid, which is then converted to carbon dioxide and water, raising blood pH. The resulting alkalinisation drives potassium into cells, reduces free ionised calcium, and facilitates renal excretion of weak acids, thereby correcting metabolic acidosis and lowering serum potassium.

Side Effects

Common Side Effects

  • Injection site pain or irritation.
  • Mild hypernatremia.
  • Transient metabolic alkalosis.
  • Fluid overload in susceptible patients.
  • Mild hypertension.
  • Hypocalcaemia.

Serious or Rare Side Effects

  • Severe metabolic alkalosis leading to respiratory depression.
  • Pulmonary oedema.
  • Life‑threatening arrhythmias.
  • Severe hypernatremia with neurological signs.
  • Anaphylactic reaction.
  • Marked electrolyte disturbances requiring intensive monitoring.

Precautions & Warnings

Before using Hylvastam, consider the following precautions:

  • Monitor serum electrolytes: check sodium, potassium, calcium, and bicarbonate levels regularly.
  • Assess acid‑base status: confirm metabolic acidosis before administration.
  • Adjust dose in renal impairment: reduced clearance may increase risk of alkalosis.
  • Avoid in congestive heart failure: fluid overload can exacerbate cardiac symptoms.
  • Use with caution in patients on diuretics: may intensify electrolyte shifts.
  • Store at ambient temperature: keep in original container, protect from moisture and direct sunlight.

Avoid Interactions

Hylvastam may interact with other medications as follows:

Major Interactions (Avoid)

  • Concurrent alkalinising agents (e.g., oral sodium bicarbonate): risk of severe metabolic alkalosis.
  • Loop diuretics combined with high‑dose bicarbonate: can cause profound electrolyte imbalance.
  • Calcium carbonate supplements: may precipitate calcium carbonate crystals.

Moderate Interactions (Monitor Closely)

  • ACE inhibitors or ARBs: altered potassium handling may increase hyperkalaemia risk.
  • NSAIDs: can impair renal function, affecting bicarbonate clearance.
  • Insulin therapy: may potentiate intracellular potassium shift, requiring close potassium monitoring.

Frequently Asked Questions

Hylvastam contains sodium hydrogen carbonate and is used intravenously to correct metabolic acidosis, lower elevated serum potassium levels, and assist in the management of certain drug overdoses by alkalinising urine.

After injection, sodium hydrogen carbonate dissociates into sodium and bicarbonate. The bicarbonate buffers excess hydrogen ions, raising blood pH, while the resulting alkalinity drives potassium into cells and promotes renal excretion of weak acids, helping restore normal acid‑base balance.

The dose of Hylvastam is determined by the prescribing clinician based on the patient’s clinical condition, laboratory values, and response to therapy. Dosage regimens are individualized and should follow the healthcare professional’s orders.

Safety of Hylvastam in pregnancy or lactation has not been definitively established. It should be used only if the potential benefit justifies any potential risk to the fetus or infant, and the decision should be made by the treating physician.

To place an order, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if needed) and import documentation.

Hylvastam delivers sodium hydrogen carbonate intravenously, offering rapid correction of acid‑base disturbances compared with oral bicarbonate formulations, which have slower onset and variable absorption. Its IV route allows precise titration in acute settings, whereas oral agents are generally reserved for chronic management.

Store Hylvastam at ambient temperature, preferably below 25 °C. Keep the vial in its original packaging, protect it from moisture and direct sunlight, and ensure the container is sealed until use to maintain sterility.

Hylvastam is administered intravenously by a qualified healthcare professional. The solution is typically diluted in compatible IV fluids and infused over a controlled period, with continuous monitoring of vital signs and laboratory parameters.

Serious risks include severe metabolic alkalosis, pulmonary oedema, life‑threatening arrhythmias, severe hypernatremia, and anaphylactic reactions. Prompt recognition and management of these events are essential, and patients should be monitored closely during and after infusion.

Hylvastam should be avoided in patients with known hypersensitivity to sodium bicarbonate, uncontrolled congestive heart failure, severe renal impairment without dose adjustment, or in those where excessive alkalinisation could be harmful. Clinical judgment is required for each individual case.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated:

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.

Related Products

Other formulations containing Sodium Hydrogen Carbonate

A

A
A

A
A

A
A

A

Browse all products →

Ordering Process

Simple, Secure, and Seamless

Learn how our streamlined ordering process guarantees fast, compliant, and reliable access to essential medicines worldwide.

Quote request form

01

Submit Quote Request Form

Tell us what medications you need by filling out our simple form and uploading a valid document.

Price estimate review

02

We Review & Send Estimate

Our licensed pharmacists will verify your details and provide you with a detailed cost estimate.

Secure payment

03

Confirm & Make Payment

Discuss any queries, approve the estimate, and complete your payment.

Worldwide delivery

04

Get Delivered

Your medicines, safely packed and delivered to your door or nearest airport — hassle-free.

Regulatory recognitions

Quality You Can Trust

Our internationally recognized certifications underscore our commitment to safety, quality, and excellence.

SGS GSDP Certification

GSDP Compliant from SGS

URS ISO 9001

URS ISO 9001 Certification

FDA Maharashtra

Licensed by FDA Maharashtra

IEC License DGFT

IEC License issued by DGFT